Together, these in vitro, in vivo and patient-level data suggest that purines, especially GTP, mediate RT-resistance, and DNA repair in IDH wild type GBM and that inhibition of GTP synthesis could be a promising therapeutic strategy for GBM, especially when combined with RT. The gene discussed is IDH1; the disease is glioblastoma.